睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 16 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 16

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京高博博仁医院Beijing Boren Hospital北京医院页面
  2. 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
  3. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  4. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  5. 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
  6. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  7. 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面
  8. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  9. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  10. 研究中心山东大学齐鲁医院Qilu Hospital of Shandong University济南医院页面
  11. 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面
  12. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  13. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
  14. 研究中心同济大学附属同济医院Tongji Hospital上海医院页面
  15. 研究中心四川大学华西医院West China Hospital成都医院页面
  16. 研究中心陆军军医大学第二附属医院(新桥医院)Xinqiao Hospital, Army Medical University重庆医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT04586478,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Received at least Rituximab or other CD20 targeted drugs containing (except CD20 negative tumors) chemotherapy and

    入选标准第 10 条

    Radiotherapy within 6 weeks prior to apheresis, including big bone marrow area (e.g., sternum or pelvis) - progressive disease at radiotherapy site, or PET positive lesion at other non-radiotherapy site is eligible; if there is existing PET positive lesion in other non-radiotherapy sites, then it is allowable to conduct radiotherapy at a single lesion within 2 weeks prior to apheresis.

    排除标准第 12 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

    入选标准第 17 条

  4. Absolute neutrophil count (ANC) > 1.0×109/L;

    入选标准第 19 条

    Platelet (PLT) ≥50×109/L;

    入选标准第 21 条

  5. Measurable imaging lesion at screening: Intranodal lesion must have a long diameter of more than 1.5 cm, and extranodal lesion must have a long diameter of more than 1.0 cm (per revised IWG Response Criteria 2014 in Lymphomas);

    入选标准第 16 条

  6. Patients complying with any of hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg) positive, hepatitis B e antibody (HBe-Ab) and/or hepatitis B core antibody (HBc-Ab) positive and HBV-DNA copies being more than the lower limit of detection, hepatitis C antibody (HCV-Ab) positive, anti-treponemia pallidum antibody (TP-Ab) positive, EBV-DNA, and CMV-DNA copies being more than the lower limit of detection.

    排除标准第 20 条

    Patients with concurrent active malignancy; those with a history of malignancy, cured for≥2 years, are eligible.

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04586478,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients who are willing to sign the informed consent form;
  2. Aged 18-75 years, male or female;
  3. At screening, subjects complying with the following diagnostic and treatment requirements:
  4. Complying with CD19-positive NHL according to the WHO classification 2017, which are provided specifically as follows:
  5. Diffuse large B cell lymphoma (DLBCL), not otherwise specified (NOS);
  6. Primary mediastinal large B cell lymphoma (PMBCL);
  7. Transformed follicular lymphoma
  8. High grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high grade B cell lymphoma - not otherwise specified.
  9. Previously received≥2nd-line adequate therapy or autologous hematopoietic stem cell transplantation (ASCT), including:
  10. Received at least Rituximab or other CD20 targeted drugs containing (except CD20 negative tumors) chemotherapy and
  11. Received at least one chemotherapy regimen containing anthracycline;
  12. Definition of line: Stable disease (SD) after receiving a first-line adequate therapy or progressive disease (PD), and SD after a second-line therapy for at least 2 cycles or PD .
  13. In relapsed or refractory status at screening:
  14. Definition of relapse: Remission (including partial remission (PR) or complete remission (CR)) after treatment with at least the standard therapy regimen (it must contain Ribuximab), and then PD;
  15. Definition of refractoriness:
  16. Measurable imaging lesion at screening: Intranodal lesion must have a long diameter of more than 1.5 cm, and extranodal lesion must have a long diameter of more than 1.0 cm (per revised IWG Response Criteria 2014 in Lymphomas);
  17. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  18. Adequate bone marrow reserve, defined as:
  19. Absolute neutrophil count (ANC) > 1.0×109/L;
  20. Absolute lymphocyte count (ALC) ≥ 0.3×109/L;
  21. Platelet (PLT) ≥50×109/L;
  22. Proper organ function, complying with the following criteria (except hepatic dysfunction due to tumor cell infiltration): Aspartate aminotransferase (AST) ≤ 3 Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) ≤ 3 ULN; Total serum bilirubin ≤ 2 ULN, unless there exists concurrent Gilbert syndrome; patients with Gilbert syndrome, with total serum bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN, may be included; Renal function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula); Minimum pulmonary reserve, defined as Grade ≤ 1 dyspnea, and blood oxygen saturation > 91% at non-oxygen inhalation status; International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 ULN.
  23. Vascular conditions for apheresis;
  24. Women with child-bearing potential are negative in blood/urine pregnancy tests within 3 d prior to apheresis, and prior to infusion of CNCT19 cell injection infusion; any male or female patient with child-bearing potential must agree to adopt effective contraceptive measures throughout the study, and at least a year after administration of the investigational therapy. As judged by the investigator, a patient with child-bearing potential means that: He/she has normal sexual life and is biologically fertile to have children. Non-fertile female patients (i.e., complying one of the following criteria):Previously received hysterectomy, bilateral ovariectomy, or bilateral tubal ligation, or Medically confirmed ovarian failure, or Medically confirmed postmenopause (amenorrhea of at least 12 consecutive months).

排除标准:Exclusion Criteria:

  1. Patients with active central nervous system (CNS) lymphoma (a patient with CNS disease symptoms must receive lumbar puncture and MRI/CT to exclude CNS lymphoma).
  2. Patients with existing central nervous system disease or with a history of central nervous system disease, e.g., epileptic seizure, cerebral ischemia/hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellum disease, organic brain syndrome, mental disease, or any autoimmune disease involved with central nervous system.
  3. Patients receiving any of the following drugs or therapies within the specified period prior to apheresis:
  4. Alemtuzumab within 6 months prior to apheresis;
  5. Cladribine within 3 months prior to apheresis;
  6. Anti-CD20 monoclonal antibody within 7 d prior to apheresis;
  7. Venetoclax (BCL-2 inhibitor) within 4 d prior to apheresis;
  8. Idelalisib (PI3Kδ kinase inhibitor) within 2 d prior to apheresis;
  9. Lenalidomide within 1 d prior to apheresis;
  10. Lymphocytotoxic chemotherapy within 2 weeks prior to apheresis - use in more than 3 half-lives prior to apheresis is eligible;
  11. Non-lymphocytotoxic chemotherapy within 7 d prior to apheresis - use in more than 3 half-lives prior to apheresis is eligible;
  12. Radiotherapy within 6 weeks prior to apheresis, including big bone marrow area (e.g., sternum or pelvis) - progressive disease at radiotherapy site, or PET positive lesion at other non-radiotherapy site is eligible; if there is existing PET positive lesion in other non-radiotherapy sites, then it is allowable to conduct radiotherapy at a single lesion within 2 weeks prior to apheresis.
  13. Patients receiving chemotherapy within 2 weeks prior to CNCT19 Cell injection infusion, excluding the following conditions:
  14. Pretreatment chemotherapy as specified by the protocol;
  15. CNS lymphoma prophylaxis by intrathecal injection (it must be stopped within 1 week prior to infusion of CNCT19 Cell Injection).
  16. Discontinuation of a systematic therapeutic hormone within 72 h prior to infusion of CNCT19 Cell Injection; however, use of the hormone in the physiological surrogate amount is eligible (e.g., Prednisone in a dose of <10 mg/d or equivalent).
  17. Patients previously received CAR-T cell therapy.
  18. Patients who have previously received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  19. Patients with known active or uncontrolled synstemic autoimmune disease and under treatment.
  20. Patients complying with any of hepatitis B surface antigen (HBsAg) and/or hepatitis B e antigen (HBeAg) positive, hepatitis B e antibody (HBe-Ab) and/or hepatitis B core antibody (HBc-Ab) positive and HBV-DNA copies being more than the lower limit of detection, hepatitis C antibody (HCV-Ab) positive, anti-treponemia pallidum antibody (TP-Ab) positive, EBV-DNA, and CMV-DNA copies being more than the lower limit of detection.
  21. Patients who received a major surgery within 4 weeks prior to screening, and are not eligible for enrollment as judged by the investigator.
  22. Patients with concurrent active malignancy; those with a history of malignancy, cured for≥2 years, are eligible.
  23. Patients complying any of the following conditions: Left ventricular ejection fraction (LVEF) ≤45% (ECHO); New York Heart Association (NYHA) Grade III or IV congestive heart failure; Uncontrolled hypertension (systolic blood pressures≥140mmHg and/or diastolic blood pressures ≥90 mmHg), pulmonary hypertension, or unstable angina pectoris; Myocardial infarction or bridging or stent procedure within 12 months prior to administration of the drug; Clinically significant valvular heart disease; Other heart diseases unsuitable for enrollment, as judged by the investigator.
  24. Patients with lymphoma involved with atrium or ventricle.
  25. Patients with clinical emergency (e.g., intestinal infarction or vascular compression) requiring treatment, due to existing lymphoma body obstruction or compression at screening.
  26. Patients with active hemorrhage at screening.
  27. Patients with deep vein thrombosis within 6 months prior to screening, or a history of pulmonary embolism.
  28. Patients who are known with a history of hypersensitivity reaction to any ingredient used for the drug product in the trial.
  29. Patients vaccinated with a live vaccine within 6 weeks prior to screening.
  30. Patients with active infection at screening.
  31. Patients with a life expectancy of less than 3 months.
  32. Patients participating in any other interventional clinical study or receiving treatment of an active investigational drug within 3 half-lives prior to CNCT19 Cell Injection infusion.

引自 ClinicalTrials.gov, NCT04586478, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04586478,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04586478